I'm going to take my best guess and say there will be no submission till after June. As they will not have all of the information until then, so push it out to September. That probably is not welcome news, but, maybe some of the results are encouraging and will prove to be valuable in the long run. Everyone knows that the sarcomas are an especially difficult target, which is one reason they were chosen, no new treatments in over 20 years and a very poor prognosis. I know Merck would not continue if the data said it was useless to do so. Basically we are looking at a postponement. How the market will react, who knows. Skal, Yo.
